Florian Simon

16PUBLICATIONS
60CO-AUTHORS
Predictive and prognostic markersMedical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursApplications in health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jul 07, 2026
Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies.

|May 12, 2026
Clinical impact of potential drug-drug interactions between midostaurin and posaconazole in FLT3-mutated AML.

|Mar 30, 2026
Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Moritz Fürstenau, Carsten Utoft Niemann, Sandra Robrecht

|Mar 17, 2026
Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemia.

Florian Simon, Rudy Ligtvoet, Moritz Fürstenau

|Nov 21, 2025
Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.

Edward R Scheffer Cliff, Thomas E Lew, Florian Simon

|Sep 11, 2025
ELEVATE-ing clinical trial reporting in CLL.

Florian Simon, Othman Al-Sawaf

Pageof 3

Frequent Collaborators

10 joint publications

Moritz Fürstenau

9 joint publications

Michael J Hallek

7 joint publications

Othman Al-Sawaf

6 joint publications

Carsten Utoft Niemann